Abstract:Introduction Helicobacter pylori is the most well-known risk factor for gastric cancer. Antibiotic resistance is the main reason for the failure of H. pylori eradication, and understanding the antibiotic resistance before treatment may be the main determinant of successful eradication of H. pylori. This study aims to evaluate the efficacy and safety of quadruple therapy based on faecal molecular antimicrobial susceptibility tests for the first-line eradication of H. pylori infection. Methods and analysis This is a single-centre, single-blind, randomised controlled trial, enrolling 855 patients with H. pylori infection. Patients are randomised to three groups for a 14-day treatment: group A: amoxicillin- and clarithromycin-based bismuth-containing quadruple therapy (BQT) (rabeprazole 10mg, amoxicillin 1 g, clarithromycin 500mg and colloidal bismuth 200mg two times per day); group B: clarithromycin medication history-based BQT (rabeprazole 10 mg, amoxicillin 1 g, furazolidone 100 mg (with clarithromycin medication history)/clarithromycin 500 mg (without clarithromycin medication history) and colloidal bismuth 200mg two times per day); group C: antimicrobial susceptibility test-based BQT (rabeprazole 10 mg, amoxicillin 1 g, clarithromycin 500 mg (clarithromycin-sensitive)/ furazolidone 100 mg (clarithromycin resistant) and colloidal bismuth 200mg two times per day). The primary end point is the eradication rate. The secondary end points are the incidence of adverse events and compliance. Ethics and dissemination This study was approved by the Ethics Committee of Second Affiliated Hospital, School of Medicine, Zhejiang University (Number 20230103). The results will be published in the appropriate peer-reviewed journal.

Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease

Effect of cimetidine treatment in the prevention of gastric ulcer relapse: a one year double blind multicentre study.

Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer.

The Evolution of Anti-Ulcer Therapy with Cimetidine. Is a Single Large Nocturnal Dose of Cimetidine the Right Therapy for Duodenal Ulcer?

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Cimetidine-associated adverse reaction

Short term treatment of gastric ulcer: a comparison of sucralfate and cimetidine.

Maintenance therapy: a two year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence.

Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review

Review: eradication of Helicobacter pylori. Problems and recommendations

[Ranitidine and cimetidine in the prevention of stress: ulcer hemorrhage a prospective comparative multicenter study]

Management of Helicobacter pylori-related disorders

New insight into the control of peptic ulcer by targeting the histamine H2 receptor

Cimetidine Attenuates Therapeutic Effect of Anti-PD-1 and Anti-PD-L1 and Modulates Tumor Microenvironment in Colon Cancer

[The differentiated treatment of patients with duodenal peptic ulcer]

Therapeutic Effect and Mechanism of Hydrotalcite on Experimental Gastric Ulcer

Eradication of Helicobacter pylori: recent advances in treatment

Efficacy and safety of proton pump inhibitors and H2 receptor antagonists in the initial non‑eradication treatment of duodenal ulcer: A network meta‑analysis

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

High-dose dual therapy versus bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection – A review of the strengths, weaknesses, and proposed solutions

Vonoprazan: A Review in Helicobacter pylori Infection